Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

2.820 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Price and Volume

Volume	71,589
Open	2.820
Bid (Size)	2.780 (900)
Ask (Size)	2.820 (200)
Prev. Close	2.820
Today's Range	2.750 - 2.910
52wk Range	2.800 - 13.65
Shares Outstanding	11,586,406
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

November 26, 2025

$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants

From Tempest Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 20, 2025

Via Benzinga

Performance

YTD	-4.4%	-4.4%
1 Month	-9.3%	-9.3%
3 Month	-74.0%	-74.0%
6 Month	-60.2%	-60.2%
1 Year	-77.1%	-77.1%

More News

Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition

November 19, 2025

Via MarketMinute

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

November 25, 2025

From Tempest Therapeutics

Via GlobeNewswire

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction ↗

November 19, 2025

Via Stocktwits

Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗

November 19, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 19, 2025

Via Benzinga

Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast ↗

November 19, 2025

Via Benzinga

Why Tempest Therapeutics (TPST) Stock Is Down 45% Today ↗

November 19, 2025

Via Benzinga

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

November 19, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

November 05, 2025

From Tempest Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 04, 2025

Via Benzinga

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

June 30, 2025

From Tempest Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 11, 2025

Via Benzinga

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025

From Tempest Therapeutics

Via GlobeNewswire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

June 09, 2025

Via Chartmill

Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

June 09, 2025

Via Benzinga

Get insights into the top gainers and losers of Monday's pre-market session. ↗

June 09, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 09, 2025

Via Benzinga

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 05, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

April 28, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

April 21, 2025

From Tempest Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Tempest Therapeutics, Inc. - Common Stock publicly traded?

Yes, Tempest Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Tempest Therapeutics, Inc. - Common Stock trade on?

Tempest Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Tempest Therapeutics, Inc. - Common Stock?

The ticker symbol for Tempest Therapeutics, Inc. - Common Stock is TPST on the Nasdaq Stock Market

What is the current price of Tempest Therapeutics, Inc. - Common Stock?

The current price of Tempest Therapeutics, Inc. - Common Stock is 2.820

When was Tempest Therapeutics, Inc. - Common Stock last traded?

The last trade of Tempest Therapeutics, Inc. - Common Stock was at 01/06/26 04:00 PM ET

What is the market capitalization of Tempest Therapeutics, Inc. - Common Stock?

The market capitalization of Tempest Therapeutics, Inc. - Common Stock is 32.67M

How many shares of Tempest Therapeutics, Inc. - Common Stock are outstanding?

Tempest Therapeutics, Inc. - Common Stock has 33M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.